Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NCT04390581
NCT04390581CompletedPhase 4

A Prospective Study Evaluating the Effectiveness of Juvederm Volift With Lidocaine for Treatment of the Aging Hands

Allergan2 sites in 1 country75 target enrollmentStarted: May 20, 2020Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
Phase 4
Status
Completed
Sponsor
Allergan
Enrollment
75
Locations
2
Primary Endpoint
At least a 1-point improvement in the Allergan Hand Volume Deficit Scale (AHVDS) by hand from baseline before treatment to 3-month visit.
Study OverviewStudy DesignEligibility CriteriaOutcomesInvestigatorsSitesRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

This study will evaluate the effect of Juvederm Volift with Lidocaine, an injectable gel implant, to treat aging hands of participants 35 and older.

Study Design

Study Type
Interventional
Allocation
Na
Intervention Model
Single Group
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
35 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Able to provide informed consent
  • •Female and male subjects over 35 years of age
  • •Has a desire for treatment with hyaluronic acid for skin depressions on both hands
  • •Must qualify to receive Juvéderm® VOLIFT®™ with Lidocaine as described in the current European Union Juvéderm® VOLIFT®™ with Lidocaine Directions For Use (DFU)
  • •Accepts the obligation not to receive any other hand cosmetic procedures or treatments at any time during the study (hand creams are permitted)
  • •Agrees not to change their normal hand care regimen throughout the course of the study.
  • •Women of childbearing potential must have a negative urine pregnancy test result at baseline (Day 1) and practice a reliable method of contraception throughout the study.

Exclusion Criteria

  • •All contraindications as described in the current European Union Juvéderm® VOLIFT®™ with Lidocaine Directions For Use (DFU), as supplied with the product.
  • •Receiving or planning to receive anticoagulant therapy during the course of the study, or received anticoagulant within 10 days prior to study treatment and 3 days after.
  • •Receiving or is planning to receive anti-inflammatory drugs (oral/injectable corticosteroids or NSAIDs, e.g., aspirin, ibuprofen), or other substances known to increase coagulation time (vitamins or herbal supplements, e.g., Vitamin E, gingko) for 10 days prior to study treatment and 3 days after
  • •Undergone hand surgery, tissue grafting, or tissue augmentation with silicone, fat, or other permanent, or semi-permanent dermal fillers or be planning to undergo any of these procedures at any time during the study
  • •Undergone temporary hand dermal filler injections with any substance within 12 months prior to entry in the study
  • •Noticeable scarring, active inflammation, infection, cancerous or pre-cancerous lesion, or unhealed wound or have undergone radiation treatment in the area to be treated
  • •Subject with a dental infection (e.g. infected tooth or paradonitis) or have received dental cleaning within one month of such infection
  • •Subject with history of hypertrophic scarring on hands
  • •Any fibrosis or scarring or deformities on the hands - History of neurological disease that may affect peripheral neurological function
  • •Subjects with a history of Raynaud´s disease or phenomenon, or history of other disease that may affect peripheral circulation
  • •Subjects with a history of autoimmune disease or joint disease or connective tissue disease (e.g., rheumatoid arthritis, lupus, scleroderma etc.)
  • •Woman pregnant, lactating, or planning to become pregnant at any time during the study
  • •Received any investigational product within 30 days prior to study enrollment or be planning to participate in another investigation during the course of this study
  • •Subject with any skin disease (acute and/or chronic) on the treated zone, likely to interfere with the measured parameters or to put the subject to an undue risk.
  • •Subject with multiple allergies, anaphylactic shock history, evolutive allergic pathologies.

Outcomes

Primary Outcomes

At least a 1-point improvement in the Allergan Hand Volume Deficit Scale (AHVDS) by hand from baseline before treatment to 3-month visit.

Time Frame: Month 3

The Evaluating Investigator will grade each hand using the AHVDS 5-point scale where 0= No visible tendons and veins, 1=No protruding tendons, 2=Protruding tendons, 3=Prominent tendons, 4=Tendons very prominent.

Secondary Outcomes

  • Improvement from baseline to each other post-treatment time points in the Allergan Hand Volume Deficit Scale (AHVDS).(Day 30, Month 3, Month 6, Month 9, Month 12, Month 15, and Month 18)
  • Subject improvement from baseline to each post-treatment time point using the Global Aesthetic Improvement Scale (GAIS) Subject(Day 30, Month 3, Month 6, Month 9, Month 12, Month 15, and Month 18)
  • Change in baseline in hand function based on pinch gauge test that will be used to measure any changes in hand function at each post-treatment timepoint.(Day 30, Month 3, Month 6, Month 9, Month 12, Month 15, and Month 18)
  • Injection Site Reactions (ISRs) evaluated by the subject 30 days after each injection using a subject injection site diary.(Day 30)
  • Change in baseline in hand function based on finger goniometer test that will be used to measure any changes in hand function at each post-treatment timepoint.(Day 30, Month 3, Month 6, Month 9, Month 12, Month 15, and Month 18)
  • Change in HAND-Q Hand Appearance Scale from baseline before treatment to each post-treatment timepoint(Day 30, Month 3, Month 6, Month 9, Month 12, Month 15, and Month 18)
  • Change in skin roughness from baseline before treatment to each post-treatment timepoint using PRIMOS ® 3D Lite for skin roughness measurements(Day 30, Month 3, Month 6, Month 9, Month 12, Month 15, and Month 18)
  • Change in skin moisture from baseline before treatment to each post-treatment timepoint using MoistureMeter D®(Day 30, Month 3, Month 6, Month 9, Month 12, Month 15, and Month 18)
  • Number of patients experiencing one or more treatment emergent adverse events (TEAEs)(Day 30, Month 3, Month 6, Month 9, Month 12, Month 15, and Month 18)
  • Change in baseline in hand function based on hand dynamometer test that will be used to measure any changes in hand function at each post-treatment timepoint.(Day 30, Month 3, Month 6, Month 9, Month 12, Month 15, and Month 18)
  • Investigator improvement from baseline to each post-treatment time point using the Global Aesthetic Improvement Scale (GAIS) Investigator(Day 30, Month 3, Month 6, Month 9, Month 12, Month 15, and Month 18)
  • Change in skin elasticity from baseline before treatment to each post-treatment timepoint using Cutometer®(Day 30, Month 3, Month 6, Month 9, Month 12, Month 15, and Month 18)

Investigators

Sponsor
Allergan
Sponsor Class
Industry
Responsible Party
Sponsor

Study Sites (2)

Loading locations...

Similar Trials

Completed
Phase 4
A Study to Evaluate the Effectiveness of Juvéderm® VOLIFT®™ With Lidocaine for Dynamic Radial Cheek Line Skin DepressionsCheek Line Depressions
NCT02980783Allergan53
Completed
Not Applicable
Postmarket Study of JUVÉDERM VOLBELLA™ With Lidocaine in the LipsLip Augmentation
NCT01629134Allergan Medical62
Completed
Phase 4
VFORM: Prospective, Open Label, Study to Evaluate VOLIFT With Lidocaine Treatment for FORehead Contouring and Marionette LinesMarionette Lines Forehead Contouring
NCT05077488Allergan163
Completed
Not Applicable
A Prospective, Open Label Study Evaluating JUVÉDERM® VOLBELLA With Lidocaine Treatment for the Correction of Skin Depressions in the Infra-orbital AreaInfra-orbital Skin Depressions
NCT02176421Allergan80
Completed
Not Applicable
Safety and Effectiveness of JUVÉDERM™ Injectable Gel With LidocaineNasolabial Folds
NCT00653861Allergan Medical72